2019
Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry
Ramaglia V, Sheikh-Mohamed S, Legg K, Park C, Rojas OL, Zandee S, Fu F, Ornatsky O, Swanson EC, Pitt D, Prat A, McKee TD, Gommerman JL. Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry. ELife 2019, 8: e48051. PMID: 31368890, PMCID: PMC6707785, DOI: 10.7554/elife.48051.Peer-Reviewed Original ResearchConceptsMultiple sclerosisMS disease activityT-cell phenotypeMass cytometryTypes of lymphocytesMultiple sclerosis lesionsNatalizumab cessationDisease activityMS patientsInflammatory lesionsImmune cellsSpinal cordLesion morphometryMS lesionsB cellsLesion typeSclerosis lesionsLesionsBlood vesselsCell phenotypeFunctional stateCytometryCellular contentCell-cell interactionsPhenotype
2011
What happens when natalizumab therapy is stopped?
Schaaf SM, Pitt D, Racke MK. What happens when natalizumab therapy is stopped? Expert Review Of Neurotherapeutics 2011, 11: 1247-1250. PMID: 21864070, DOI: 10.1586/ern.11.109.Peer-Reviewed Original ResearchMS disease activityDisease activityActive diseaseNatalizumab cessationTreatment interruptionMultiple sclerosisBaseline levelsSimilar disease activityProgressive multifocal leukoencephalopathyNatalizumab exposureNatalizumab therapyNatalizumab treatmentMultifocal leukoencephalopathyMS patientsMRI measuresMS treatmentEvidence of reboundDiseaseElimination kineticsNatalizumabIntegrin antagonistsTreatmentPatientsCessationLeukoencephalopathy